Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Peripheral arterial disease and isolated systolic hypertension: The ATTEST Study

Abstract

Hypertension is a risk factor for cardiovascular (CV) diseases, either coronary artery disease (CAD), peripheral artery disease (PAD) or cerebrovascular disease (CVD). The relationships between those different localizations of CV disease and the haemodynamic features of hypertension have been poorly evaluated in the past. In the ATTEST study, a geographically representative panel of 3020 general practitioners recruited 8316 consecutive patients with CV diseases (PAD, CAD or CVD, alone or in association). Blood pressure, which was not an inclusion criterion, was then measured and related to the different forms of CV diseases. Blood pressure classification involved 20% normotensive subjects, 24% subjects with controlled hypertension, 42% subjects with isolated systolic hypertension and 14% subjects with systolic–diastolic hypertension, all hypertensives with or without antihypertensive therapy. From multiple regression analysis, it appeared that subjects with systolic hypertension were characterized by the presence of PAD, with little or no presence of CAD and/or CVD. Subjects with systolic–diastolic hypertension were characterized by the presence of CAD and/or CVD, but without PAD. Although the former was only influenced by age, dyslipidaemia and diabetes mellitus influenced the latter. This study confirms the high prevalence of hypertension (80%) in a large population of patients with CV diseases selected in primary care. Analysis of different features of hypertension revealed that isolated systolic hypertension was the most prevalent form of hypertension in this treated population. Finally, one of the predominant goals of secondary prevention in subjects with PAD should be the treatment of isolated systolic hypertension.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Lawes CM, Vander Hoorn S, Rodgers A . International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371: 1513–1518.

    Article  Google Scholar 

  2. Arterial stiffness in hypertension. In: Safar ME and O'Rourke ME (eds). Handbook of Hypertension, vol. 23. Elsevier: Edinburgh, UK, 2006, pp 3–62, 75–136, 459–501.

  3. Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Bentivoglio M, Thijs L et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005; 46: 386–392.

    Article  CAS  Google Scholar 

  4. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–1187.

    Article  CAS  Google Scholar 

  5. Blacher J, Cacoub P, Luizy F, Mourad JJ, Levesque H, Benelbaz J et al. Peripheral arterial disease versus other localizations of vascular disease: the ATTEST study. J Vasc Surg 2006; 44: 314–318.

    Article  Google Scholar 

  6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.

    Article  Google Scholar 

  7. Safar ME, Smulyan H . Systolic versus diastolic blood pressure, 2000. In: Bulpitt CJ (ed). Handbook of Hypertension. Elsevier Science BV: Amsterdam, pp 73–85.

  8. Spence JD, Sibbald WJ, Cape RD . Pseudohypertension in the ederly. Clin Sci Molec Med 1978; 55: 399s–402s.

    Google Scholar 

  9. Messerli FH, Ventura HO, Amodeo C . Osler's maneuver and pseudohypertension. New Engl J Med 1985; 312: 1348–1351.

    Article  Google Scholar 

  10. Safar ME, Simon AC . Hemodynamics in systolic hypertension, 1986. In: Zanchetti A, Tarazi RC (eds). Handbook of Hypertension, vol 7: Physiopathology of Hypertension, Cardiovascular Aspects. Elsevier Science: Amsterdam, pp 70–84.

  11. Safar ME, Laurent ST, Asmar RE, Safavian A, London GM . Systolic hypertension in patients with arteriosclerosis obliterans of the lower limbs. Angiology 1987; 28: 287–295.

    Article  Google Scholar 

  12. Levenson JA, Simon AC, Fiessinger JN, Safar ME, London GM, Housset EM . Systemic arterial compliance in patients with arteriosclerosis obliterans of the lower limbs; Observation of the effect of intravenous propranolol. Arteriosclerosis 1982; 2: 266–271.

    Article  CAS  Google Scholar 

  13. Levenson JA, Simon ACH, Safar ME, Fiessinger JN, Housset EM . Systolic hypertension in patients with arteriosclerosis of the lower limbs. Clin Exper Hyper Theory Practice 1982; A4 (7): 1059–1072.

    Google Scholar 

  14. Van Popele NM, Grobbee DE, Bots ML, Asmar R, Topouchian J, Reneman RS et al. Association between arterial stiffness and atherosclerosis. The Rotterdam Study. Stroke 2001; 32: 454–460.

    Article  CAS  Google Scholar 

  15. Labouret G, Achimastos A, Benetos A, Safar M, Housset E . L'hypertension artérielle des amputés traumatiques. Press Med 1983; 21: 1349–1354.

    Google Scholar 

  16. Levenson JA, Simon AC, Maarek BE, Gitelman RJ, Fiessinger JN, Safar ME . Regional compliance of brachial artery and saline infusion in patients with arteriosclerosis obliterans. Arteriosclerosis 1985; 5: 80–87.

    Article  CAS  Google Scholar 

  17. Achimastos A, Brahimi M, Raison J, Billaud E, Ayache M, Moatti N et al. Plasma insulin, plasminogen activator inhibitor, and ankle-brachial systolic blood pressure ratio in overweight hypertensive subjects. J Hum Hypertens 1999; 13: 329–335.

    Article  CAS  Google Scholar 

  18. Simon AC, Levenson JA, Levy BI, Bouthier JE, Peronneau PP, Safar ME . Effects of nitroglycerine on peripheral large arteries in hypertension. Br J Clin Pharmacol 1982; 14: 241–245.

    Article  CAS  Google Scholar 

  19. Louie J, Isaacson JA, Zierler RE, Bergelin RO, Strandness DE . Prevalence of carotid and lower extremity arterial disease in patients with renal artery stenosis. Am J Hypertens 1994; 7: 436–439.

    Article  CAS  Google Scholar 

  20. Brewer LC, Chai HS, Bailey KR, Kullo IJ . Measures of arterial stiffness and wave reflection are associated with walking distance in patients with peripheral arterial disease. Atherosclerosis 2007; 191: 384–390.

    Article  CAS  Google Scholar 

  21. Safar ME, Totomoukouo JJ, Asmar RA, Laurent ST . Increased pulse pressure in patients with arteriosclerosis obliterans of the lower limb. Arteriosclerosis 1987; 7: 232–237.

    Article  CAS  Google Scholar 

  22. Farrar DJ J, Malindzak GS, Johnson G . Large Vessel Impedance in Peripheral Atherosclerosis. Circulation 1977; 56 (3 Suppl II): 171–178.

    Google Scholar 

  23. Yusuf S, Sleight P, Pogue J, Boch J, Davies R, Dagenais G . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–153.

    Article  CAS  Google Scholar 

  24. Achimastos AA, Natoli AK, Lawler A, Blombery PA, Kingwell BA . Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture. Hypertension 2005; 45: 1194–1199.

    Article  Google Scholar 

  25. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 995–1001.

    Article  Google Scholar 

  26. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317–1324.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work has been made possible by Bristol–Myers Squibb and Sanofi Aventis, France. Members of the scientific committee would like to acknowledge the contribution of each general practitioner. This analysis was performed with the help of GPH-CV (Groupe de Pharmacologie et d′Hémodynamique Cardiovasculaire), Paris. We thank Benjamin Regnault for statistical analysis and Dr Anne Safar for helpful and stimulating discussions.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J Blacher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Safar, M., Priollet, P., Luizy, F. et al. Peripheral arterial disease and isolated systolic hypertension: The ATTEST Study. J Hum Hypertens 23, 182–187 (2009). https://doi.org/10.1038/jhh.2008.121

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2008.121

Keywords

This article is cited by

Search

Quick links